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The replacement of injured heart tissues with the bioengineered cardiac tissues is expected as a possible 
therapeutic strategy for heart failure. Currently pluripotent stem cells are the most potent cell source for cardiac 
cells. However the risk of tumor formation due to the remaining undifferentiated stem cells in the bioengineered 
tissues remains resolved. We previously developed the scalable three-dimensional suspension bioreactor for 
human iPS cells and also the culture strategy for cardiac differentiation. Since some conditions including 
temperature, agitation rate, pH and dissolved oxygen concentration are continuously monitored and regulated in 
the bioreactor, it might be ideal to eliminate undifferentiated iPS cells in the process of cardiac differentiation 
with the optimization of these conditions. In the present study, we show that TRPV-1 activation through transient 
culture at 42 °C or with agonists is a simple and useful strategy to eliminate iPS cells from bioengineered 
cardiac cell sheet tissues. When feeder free human iPS cells were cultured at 42 °C, almost all cells 
disappeared by 48 hours through apoptosis. Furthermore when iPS cells were co-cultured with iPS cell-derived 
cardiac cells at 42 °C for 2 days, the number of Oct4 expressing iPS cells was significantly decreased. 
Conversely, in spite of cultivation at 42 °C, the number of iPS cell-derived cardiomyocytes and fibroblasts was 
maintained, and cardiac cell sheets were fabricated after reducing the temperature. TRPV-1 expression in iPS 
cells was upregulated at 42 °C, and the expression levels were significantly higher than that in cardiomyocytes, 
suggesting that iPS cells might be more sensitive to TRPV-1 activation than cardiomyocytes, which lead to 
eliminate iPS cells effectively without affecting cardiomyocyte viability. When cardiac cell sheets were cultured 
at 42 °C or with TRPV-1 agonist for 2 days, the expression of Lin28 and the number of Lin28 expressing cells 
were significantly decreased. Furthermore when 42 °C cultivation was applied to the later stage of cardiac 
differentiation in bioreactor, Lin28 expression was also significantly decreased. These findings suggest that the 
difference in tolerance to TRPV-1 activation between iPS cells and iPS cell-derived cardiac cells could be 
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